SEARCH

SEARCH BY CITATION

References

  • Allen C. L. and Bayraktutan U. (2009) Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke 4, 461470.
  • Amadi-Obi A., Yu C. R., Dambuza I., Kim S. H., Marrero B. and Egwuagu C. E. (2012) Interleukin 27 induces the expression of complement factor H (CFH) in the retina. PLoS ONE 7, e45801.
  • Arumugam T. V., Tang S. C., Lathia J. D. et al. (2007) Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl Acad. Sci. USA 104, 1410414109.
  • Arumugam T. V., Woodruff T. M., Lathia J. D., Selvaraj P. K., Mattson M. P. and Taylor S. M. (2009) Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 158, 10741089.
  • van Beek J., Elward K. and Gasque P. (2003) Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann. N. Y. Acad. Sci. 992, 5671.
  • Cardinaux J. R., Allaman I. and Magistretti P. J. (2000) Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia 29, 9197.
  • Cervera A., Planas A. M., Justicia C., Urra X., Jensenius J. C., Torres F., Lozano F. and Chamorro A. (2010) Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS ONE 5, e8433.
  • Chakraborti T., Mandal A., Mandal M., Das S. and Chakraborti S. (2000) Complement activation in heart diseases:role of oxidants. Cell. Signal. 12, 607617.
  • Cojocaru I. M., Cojocaru M., Tanasescu R., Burcin C., Atanasiu A. N., Petrescu A. M., Mitu A. C., Iliescu I. and Dumitrescu L. (2008) Changes in plasma levels of complement in patients with acute ischemic stroke. Rom. J. Intern. Med. 46, 7780.
  • Cowell R. M., Plane J. M. and Silverstein F. S. (2003) Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J. Neurosci. 23, 94599468.
  • Crehan H., Hardy J. and Pocock J. (2012) Microglia, Alzheimer's disease, and complement. Int. J. Alzheimers Dis. 2012, 983640.
  • Daha M. R. (2010) Role of complement in innate immunity and infections. Crit. Rev. Immunol. 30, 4752.
  • Daveau M., Benard M., Scotte M., Schouft M.-T., Hiron M., Francois A., Salier J.-P. and Fontaine M. (2004) Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat. J. Immunol. 173, 34183424.
  • Ducruet A. F., Zacharia B. E., Hickman Z. L., Grobelny B. T., Yeh M. L., Sosunov S. A. and Connolly E. S. Jr (2009) The complement cascade as a therapeutic target in intracerebral hemorrhage. Exp. Neurol. 219, 398403.
  • Ducruet A. F., Zacharia B. E., Sosunov S. A. et al. (2012) Complement inhibition promotes endogenous neurogenesis and sustained anti-inflammatory neuroprotection following reperfused stroke. PLoS ONE 7, e38664.
  • Epstein C. J., Avraham K. B., Lovett M., Smith S., Elroy-Stein O., Rotman G., Bry C. and Groner Y. (1987) Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc. Natl Acad. Sci. USA 84, 80448048.
  • Fan J. D., Wagner B. L. and McDonnell D. P. (1996) Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol. Endocrinol. 10, 16051616.
  • Folbergrová J., Zhao Q., Katsura K.-I. and Siesjö B. K. (1995) N-tert-butyl-α-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia. Proc. Natl Acad. Sci. USA 92, 50575061.
  • Frank M. M. and Fries L. F. (1991) The role of complement in inflammation and phagocytosis. Immunol. Today 12, 322326.
  • Gasque P., Dean Y. D., McGreal E. P., VanBeek J. and Morgan B. P. (2000) Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49, 171186.
  • Ginsberg M. D. (2008) Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55, 363389.
  • Hu H. T., Xiao F., Yan Y. Q., Wen S. Q. and Zhang L. (2012) The prognostic value of serum tau in patients with intracerebral hemorrhage. Clin. Biochem. 45, 13201324.
  • Huang Y., Qiao F., Atkinson C., Holers V. M. and Tomlinson S. (2008) A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J. Immunol. 181, 80688076.
  • Huber-Lang M., Sarma J. V., Zetoune F. S. et al. (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12, 682687.
  • Jendrysik M. A., Vasilevsky S., Yi L., Wood A., Zhu N., Zhao Y., Koontz S. M. and Jackson S. H. (2011) NADPH oxidase-2 derived ROS dictates murine DC cytokine-mediated cell fate decisions during CD4 T helper-cell commitment. PLoS ONE 6, e28198.
  • Juan T. S.-C., Wilson D. R., Wilde M. D. and Darlington G. J. (1993) Participation of the transcription factor C/EBPδ in the acute-phase regulation of the human gene for complement component C3. Proc. Natl Acad. Sci. USA 90, 25842588.
  • Kim G. W., Kondo T., Noshita N. and Chan P. H. (2002) Manganese superoxide dismutase deficiency exacerbates cerebral infarction after focal cerebral ischemia/reperfusion in mice: implications for the production and role of superoxide radicals. Stroke 33, 809815.
  • Kinouchi H., Epstein C. J., Mizui T., Carlson E., Chen S. F. and Chan P. H. (1991) Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc. Natl Acad. Sci. USA A88, 1115811162.
  • Kuroda S., Katsura K.-I., Hillered L., Bates T. E. and Siesjö B. K. (1996) Delayed treatment with α-phenyl-N-tert-butyl nitrone (PBN) attenuates secondary mitochondrial dysfunction after transient focal cerebral ischemia in the rat. Neurobiol. Dis. 3, 149157.
  • Lancelot E., Revaud M. L., Boulu R. G., Plotkine M. and Callebert J. (1997) alpha-Phenyl-N-tert-butylnitrone attenuates excitotoxicity in rat striatum by preventing hydroxyl radical accumulation. Free Radic. Biol. Med. 23, 10311034.
  • Lévi-Strauss M. and Mallat M. (1987) Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J. Immunol. 139, 23612366.
  • Lewén A. and Hillered L. (1998) Involvement of reactive oxygen species in membrane phospholipid breakdown and energy perturbation after traumatic brain injury in the rat. J. Neurotrauma 15, 521530.
  • Li Y., Copin J.-C., Reola L. F., Calagui B., Gobbel G. T., Chen S. F., Sato S., Epstein C. J. and Chan P. H. (1998) Reduced mitochondrial manganese-superoxide dismutase activity exacerbates glutamate toxicity in cultured mouse cortical neurons. Brain Res. 814, 164170.
  • Liu X. L., Wiklund L., Nozari A., Rubertsson S. and Basu S. (2003) Differences in cerebral reperfusion and oxidative injury after cardiac arrest in pigs. Acta Anaesthesiol. Scand. 47, 958967.
  • Lockwood S. F. and Gross G. J. (2005) Disodium disuccinate astaxanthin (Cardax): antioxidant and antiinflammatory cardioprotection. Cardiovasc. Drug Rev. 23, 199216.
  • Maranto J., Rappaport J. and Datta P. K. (2008) Regulation of complement component C3 in astrocytes by IL-1β and morphine. J. Neuroimmune Pharmacol. 3, 4351.
  • Mastellos D., Papadimitriou J. C., Franchini S., Tsonis P. A. and Lambris J. D. (2001) A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J. Immunol. 166, 24792486.
  • Miyajima T. and Kotake Y. (1995) Spin trapping agent, phenyl N-tert-butyl nitrone, inhibits induction of nitric oxide synthase in endotoxin-induced shock in mice. Biochem. Biophys. Res. Commun. 215, 114121.
  • Mocco J., Mack W. J., Ducruet A. F. et al. (2006) Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ. Res. 99, 209217.
  • Montalto M. C., Hart M. L., Jordan J. E., Wada K. and Stahl G. L. (2003) Role for complement in mediating intestinal nitric oxide synthase-2 and superoxide dismutase expression. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G197G206.
  • Morgan B. P. and Gasque P. (1996) Expression of complement in the brain: role in health and disease. Immunol. Today 17, 461466.
  • Nylen K., Csajbok L. Z., Ost M., Rashid A., Blennow K., Nellgard B. and Rosengren L. (2007) Serum glial fibrillary acidic protein is related to focal brain injury and outcome after aneurysmal subarachnoid hemorrhage. Stroke 38, 14891494.
  • Papp K., Vegh P., Tchorbanov A., Vassilev T., Erdei A. and Prechl J. (2010) Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr mice. Rheumatology (Oxford) 49, 22732280.
  • Pavlovski D., Thundyil J., Monk P. N., Wetsel R. A., Taylor S. M. and Woodruff T. M. (2012) Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J. 26, 36803690.
  • Qu H., Ricklin D. and Lambris J. D. (2009) Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 47, 185195.
  • Rahpeymai Y., Hietala M. A., Wilhelmsson U. et al. (2006) Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J. 25, 13641374.
  • Schaefer M., Konrad S., Thalmann J., Rheinheimer C., Johswich K., Sohns B. and Klos A. (2005) The transcription factors AP-1 and Ets are regulators of C3a receptor expression. J. Biol. Chem. 280, 4211342123.
  • Schiff L., Hadker N., Weiser S. and Rausch C. (2012) A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol. Diagn. Ther. 16, 7992.
  • Song Y. S., Lee Y.-S., Narasimhan P. and Chan P. H. (2007) Reduced oxidative stress promotes NF-κB-mediated neuroprotective gene expression after transient focal cerebral ischemia: lymphocytotrophic cytokines and antiapoptotic factors. J. Cereb. Blood Flow Metab. 27, 764775.
  • Spychalowicz A., Wilk G., Sliwa T., Ludes D. and Guzik T. J. (2012) Novel therapeuric approaches in limiting oxidative stress and inflammation. Curr. Pharm. Biotechnol. PMID: 22280420.
  • Stokowska A., Olsson S., Holmegaard L., Jood K., Blomstrand C., Jern C. and Pekna M. (2011) Plasma C3 and C3a levels in cryptogenic and large-vessel disease stroke: associations with outcome. Cerebrovasc. Dis. 32, 114122.
  • Strey C. W., Markiewski M., Mastellos D., Tudoran R., Spruce L. A., Greenbaum L. E. and Lambris J. D. (2003) The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 198, 913923.
  • Taskapilioglu M. O., Alkan T., Goren B., Tureyen K., Sahin S., Taskapilioglu O. and Korfali E. (2009) Neuronal protective effects of focal ischemic pre- and/or postconditioning on the model of transient focal cerebral ischemia in rats. J. Clin. Neurosci. 16, 693697.
  • Tsai T. H., Chen Y. L., Lin H. S., Chang H. W., Lu C. H., Chang W. N., Chen S. F., Wu C. J., Leu S. and Ko S. F. (2012) Link between lipoprotein-associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke. J. Atheroscler. Thromb. 19, 523531.
  • Tsuji M., Inanami O. and Kuwabara M. (2000) Neuroprotective effect of α-phenyl-N-tert-butylnitrone in gerbil hippocampus is mediated by the mitogen-activated protein kinase pathway and heat shock proteins. Neurosci. Lett. 282, 4144.
  • Väkevä A. and Meri S. (1998) Complement activation and regulator expression after anoxic injury of human endothelial cells. APMIS 106, 11491156.
  • Vakeva A., Morgan B. P., Tikkanen I., Helin K., Laurila P. and Meri S. (1994) Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am. J. Pathol. 144, 13571368.
  • Vibo R., Korv J., Roose M., Kampus P., Muda P., Zilmer K. and Zilmer M. (2007) Acute phase proteins and oxidised low-density lipoprotein in association with ischemic stroke subtype, severity and outcome. Free Radic. Res. 41, 282287.
  • Vik D. P., Amiguet P., Moffat G. J., Fey M., Amiguet-Barras F., Wetsel R. A. and Tack B. F. (1991) Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence. Biochemistry 30, 10801085.
  • Whiteley W., Wardlaw J., Dennis M. Lowe G., Rumley A., Sattar N., Welsh P., Green A., Andrews M. and Sandercock P. (2012) The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 43, 8691.
  • Won K. A. and Baumann H. (1990) The cytokine response element of the rat alpha 1-acid glycoprotein gene is a complex of several interacting regulatory sequences. Mol. Cell. Biol. 10, 39653978.
  • Xi G., Hua Y., Keep R. F., Younger J. G. and Hoff J. T. (2001) Systemic complement depletion diminishes perihematomal brain edema in rats. Stroke 32, 162167.
  • Yamaguchi T., Sano K., Takakura K., Saito I., Shinohara Y., Asano T. and Yasuhara H. (1998) Ebselen in acute ischemic stroke.A placebo-controlled, double-blind clinical trial. Stroke 29, 1217.
  • Yang J. P., Liu H. J., Wang Z. L., Cheng S. M., Cheng X., Xu G. L. and Liu X. F. (2009) The dose-effectiveness of intranasal VEGF in treatment of experimental stroke. Neurosci. Lett. 461, 212216.
  • Yang C. M., Lin C. C., Lee I. T., Lin Y. H., Chen W. J., Jou M. J. and Hsiao L. D. (2012) Japanese encephalitis virus induces matrix metalloproteinase-9 expression via a ROS/c-Src/PDGFR/PI3K/Akt/MAPKs-dependent AP-1 pathway in rat brain astrocytes. J. Neuroinflammation 9, 12.
  • Yong V. W. and Rivest S. (2009) Taking advantage of the systemic immune system to cure brain diseases. Neuron 64, 5560.
  • Yu S. C., Kuo C. L., Huang C. S., Chang C. S., Wu S. L., Su S. L. and Liu C. S. (2012) Endogenous granulocyte colony-stimulating factor: a biomarker in acute ischemic stroke. Biomarkers 17, 319324.
  • del Zoppo G. J. (1999) In stroke, complement will get you nowhere. Nat. Med. 5, 995996.